The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells.
Increased osteoclast-mediated bone resorption is characteristic of osteoporosis, malignant bone disease and inflammatory arthritis. Targeted deletion of Sirtuin1 (Sirt1), a key player in aging and metabolism, in osteoclasts results in increased osteoclast-mediated bone resorption in vivo, making it...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4520518?pdf=render |
| _version_ | 1828815663298248704 |
|---|---|
| author | Irina Gurt Hanna Artsi Einav Cohen-Kfir Gilad Hamdani Gal Ben-Shalom Ben Feinstein Madi El-Haj Rivka Dresner-Pollak |
| author_facet | Irina Gurt Hanna Artsi Einav Cohen-Kfir Gilad Hamdani Gal Ben-Shalom Ben Feinstein Madi El-Haj Rivka Dresner-Pollak |
| author_sort | Irina Gurt |
| collection | DOAJ |
| description | Increased osteoclast-mediated bone resorption is characteristic of osteoporosis, malignant bone disease and inflammatory arthritis. Targeted deletion of Sirtuin1 (Sirt1), a key player in aging and metabolism, in osteoclasts results in increased osteoclast-mediated bone resorption in vivo, making it a potential novel therapeutic target to block bone resorption. Sirt1 activating compounds (STACs) were generated and were investigated in animal disease models and in humans however their mechanism of action was a source of controversy. We studied the effect of SRT2183 and SRT3025 on osteoclastogenesis in bone-marrow derived macrophages (BMMs) in vitro, and discovered that these STACs inhibit RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT2183 and SRT3025 activated AMPK, increased Sirt1 expression and decreased RelA/p65 lysine310 acetylation, critical for NF-κB activation, and an established Sirt1 target. However, inhibition of osteoclastogenesis by these STACs was also observed in BMMs derived from sirt1 knock out (sirt1-/-) mice lacking the Sirt1 protein, in which neither AMPK nor RelA/p65 lysine 310 acetylation was affected, confirming that these effects require Sirt1, but suggesting that Sirt1 is not essential for inhibition of osteoclastogenesis by these STACs under these conditions. In sirt1 null osteoclasts treated with SRT2183 or SRT3025 Sirt3 was found to be down-regulated. Our findings suggest that SRT2183 and SRT3025 activate Sirt1 and inhibit RANKL-induced osteoclastogenesis in vitro however under conditions of Sirt1 deficiency can affect Sirt3. As aging is associated with reduced Sirt1 level and activity, the influence of STACs on Sirt3 needs to be investigated in vivo in animal and human disease models of aging and osteoporosis. |
| first_indexed | 2024-12-12T10:48:54Z |
| format | Article |
| id | doaj.art-f8e8f916b6a848a0b735e08c343c50b8 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-12T10:48:54Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f8e8f916b6a848a0b735e08c343c50b82022-12-22T00:26:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013439110.1371/journal.pone.0134391The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells.Irina GurtHanna ArtsiEinav Cohen-KfirGilad HamdaniGal Ben-ShalomBen FeinsteinMadi El-HajRivka Dresner-PollakIncreased osteoclast-mediated bone resorption is characteristic of osteoporosis, malignant bone disease and inflammatory arthritis. Targeted deletion of Sirtuin1 (Sirt1), a key player in aging and metabolism, in osteoclasts results in increased osteoclast-mediated bone resorption in vivo, making it a potential novel therapeutic target to block bone resorption. Sirt1 activating compounds (STACs) were generated and were investigated in animal disease models and in humans however their mechanism of action was a source of controversy. We studied the effect of SRT2183 and SRT3025 on osteoclastogenesis in bone-marrow derived macrophages (BMMs) in vitro, and discovered that these STACs inhibit RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT2183 and SRT3025 activated AMPK, increased Sirt1 expression and decreased RelA/p65 lysine310 acetylation, critical for NF-κB activation, and an established Sirt1 target. However, inhibition of osteoclastogenesis by these STACs was also observed in BMMs derived from sirt1 knock out (sirt1-/-) mice lacking the Sirt1 protein, in which neither AMPK nor RelA/p65 lysine 310 acetylation was affected, confirming that these effects require Sirt1, but suggesting that Sirt1 is not essential for inhibition of osteoclastogenesis by these STACs under these conditions. In sirt1 null osteoclasts treated with SRT2183 or SRT3025 Sirt3 was found to be down-regulated. Our findings suggest that SRT2183 and SRT3025 activate Sirt1 and inhibit RANKL-induced osteoclastogenesis in vitro however under conditions of Sirt1 deficiency can affect Sirt3. As aging is associated with reduced Sirt1 level and activity, the influence of STACs on Sirt3 needs to be investigated in vivo in animal and human disease models of aging and osteoporosis.http://europepmc.org/articles/PMC4520518?pdf=render |
| spellingShingle | Irina Gurt Hanna Artsi Einav Cohen-Kfir Gilad Hamdani Gal Ben-Shalom Ben Feinstein Madi El-Haj Rivka Dresner-Pollak The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS ONE |
| title | The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. |
| title_full | The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. |
| title_fullStr | The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. |
| title_full_unstemmed | The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. |
| title_short | The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. |
| title_sort | sirt1 activators srt2183 and srt3025 inhibit rankl induced osteoclastogenesis in bone marrow derived macrophages and down regulate sirt3 in sirt1 null cells |
| url | http://europepmc.org/articles/PMC4520518?pdf=render |
| work_keys_str_mv | AT irinagurt thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT hannaartsi thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT einavcohenkfir thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT giladhamdani thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT galbenshalom thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT benfeinstein thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT madielhaj thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT rivkadresnerpollak thesirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT irinagurt sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT hannaartsi sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT einavcohenkfir sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT giladhamdani sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT galbenshalom sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT benfeinstein sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT madielhaj sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells AT rivkadresnerpollak sirt1activatorssrt2183andsrt3025inhibitranklinducedosteoclastogenesisinbonemarrowderivedmacrophagesanddownregulatesirt3insirt1nullcells |